| Date Filed | Type | Description |
| 08/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 08/02/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/02/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/15/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/04/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/03/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results Full-year 2022 revenue was up 46% over 2021 to $137 million, meeting top end of guided range Delivered 44,419 total test reports in 2022, an increase of 58% compared to 2021",
"137.0 2017 2018 2019 2020 2021 2022 10,614 13,445 17,055 18,185 28,145 44,419 2017 2018 2019 2020 2021 2022" |
|
| 02/09/2023 |
SC 13G/A
| WASATCH ADVISORS INC reports a 12.2% stake in Castle Biosciences Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/20/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/09/2023 |
8-K
| Quarterly results |
| 12/28/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/15/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/02/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/02/2022 |
8-K
| Quarterly results |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/08/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/09/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/09/2022 |
8-K
| Quarterly results |
| 05/02/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/21/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/07/2022 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 04/04/2022 |
8-K
| Acquisition/merger/asset purchase announced |
| 03/17/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 02/28/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
|